2 results match your criteria: "Molecular and Clinical Oncology of Human Solid Tumors[Affiliation]"
Oncogene
December 2005
Molecular and Clinical Oncology of Human solid tumors, Université Pierre et Marie Curie, Hôpital Saint-Antoine, 75571 Paris Cedex 12, France.
Oncogene
December 2005
INSERM U673, Molecular and Clinical Oncology of Human Solid Tumors, Hôpital Saint-Antoine, 184 Rue du faubourg Saint-Antoine, 75571 Paris Cedex 12, France.
We recently reported that proteinase-activated receptors type I (PAR-1) are coupled to both negative and positive invasion pathways in colonic and kidney cancer cells cultured on collagen type I gels. Here, we found that treatments with the cell-permeant analog 8-Br-cGMP and the soluble guanylate cyclase activator BAY41-2272, and Rho kinase (ROK) inhibition by Y27632 or a dominant negative form of ROK lead to PAR-1-mediated invasion through differential Rac1 and Cdc42 signaling. Hypoxia or the counteradhesive matricellular protein SPARC/BM-40 (SPARC: secreted protein acidic rich in cysteine) overexpressed during cancer progression also commutated PAR-1 to cellular invasion through the cGMP/protein kinase G (PKG) cascade, RhoA inactivation, and Rac1-dependent or -independent signaling.
View Article and Find Full Text PDF